What is Arrowhead Research's market cap?

Arrowhead Research (ARWR) has a market capitalization of $12.0B and trades on NASDAQ.

What is Arrowhead Research's revenue and profitability?

Arrowhead Research generated $622.0M in trailing twelve-month revenue with a net loss of $300.9M, representing a net margin of -48.4%, with free cash flow of $561.0M. These figures are based on the Q1 2026 filing.

Who are Arrowhead Research's competitors?

Arrowhead Research's key competitors include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Scienture Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Arrowhead Research partner with?

Arrowhead Research's notable partners include Sarepta Therapeutics, Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, and others.

Where is Arrowhead Research headquartered?

Arrowhead Research is headquartered in United States of America and employs approximately 525 people. It has been publicly traded since 1995.

Arrowhead Research

ARWR

Arrowhead Pharmaceuticals is a commercial-stage biotechnology company specializing in medicines that treat intractable diseases by silencing causative genes.

Market cap

$12.05B+455%

Revenue$622.0M+14.1%

Net income-$300.9M-109%

Free cash flow$561.0M+198%

EPS (diluted)-$2.15-54.7%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

May 7, 2026

Revenue$73.7MMiss by $104.7K EPS-$0.93Beat by $0.25

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$44.2M

EPS estimate-$1.28

Financials

Q2 2026

Income statement

See full

Revenue$73.7M-86.4%

Operating income-$141.3M-137%

Net income-$132.7M-136%

EPS (diluted)-$0.93-134%

Balance sheet

See full

Cash & equivalents$188.5M+1.5%

Total debt$107.9M-5.6%

Total equity$614.0M-10.1%

Total assets$2.3B+44.2%

Cash flow

See full

Operating cash flow$84.4M-81.6%

CapEx$2.6M-51.6%

Free cash flow$81.9M-82.0%

Valuation & ratios

Valuation

See full

Market cap$12.05B+455%

Enterprise value$11.97B+439%

P/S19.4×+15.5×

Profitability

See full

Operating margin-35.7%+63.6pp

Net margin-48.4%+240pp

Returns & leverage

See full

Return on equity-46.4%+341pp

Debt / equity0.2×0.0×

Current ratio6.2×+1.1×

Competitors

By market cap

ALN

Alnylam Pharmaceuticals$37.2B-12.2%

Arrowhead Research$12.0B+439%

Ionis Pharmaceuticals$9.2B+41.1%

Ultragenyx Pharmaceutical$2.6B+1.5%

Zevra Therapeutics, Inc.$574.0M-2.9%

Fulcrum Therapeutics, Inc.$248.5M-41.0%

RFL

Rafael Holdings, Inc.$118.6M+66.4%

SCN

Scienture Holdings, Inc.$14.9M-43.4%

By revenue growth

Zevra Therapeutics, Inc.+201%

ALN

Alnylam Pharmaceuticals+82.6%

RFL

Rafael Holdings, Inc.+33.9%

Arrowhead Research+14.1%

Ultragenyx Pharmaceutical+13.5%

Ionis Pharmaceuticals-7.4%

By net margin

Zevra Therapeutics, Inc.101.58%+328pp

ALN

Alnylam Pharmaceuticals11.72%+21.5pp

Arrowhead Research-48.38%-22.0pp

Ionis Pharmaceuticals-64.7%-36.3pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

RFL

Rafael Holdings, Inc.-2,117.24%+1,010pp

Profile

Arrowhead Pharmaceuticals is a commercial-stage biotechnology company specializing in medicines that treat intractable diseases by silencing causative genes. The company utilizes a proprietary portfolio of RNA chemistries and delivery mechanisms to trigger RNA interference (RNAi), inducing deep and durable knockdown of target genes across a diverse clinical pipeline.

Competitive position

Arrowhead is a leader in the RNAi space, having transitioned from a R&D-focused entity to a commercial-stage organization with a robust pipeline of 18 clinical candidates.

GeographiesUnited States, Global

Customer segmentsRare disease patients, Healthcare providers, Global pharmaceutical companies

Business modelProduct-based, IP Licensing, Research and Development

SuppliersRaw material suppliers for RNA synthesis, Contract Research Organizations (CROs), Specialized laboratory equipment providers

CustomersSpecialty drug distributors, Health insurance payers, Medical institutions

CountryUnited States of America

Listed1995

Employees525.0

CEOChristopher R. Anzalone

SectorHealthcare

IndustryBiotechnology

Websitearrowheadpharma.com

FilingsSEC EDGAR

Ask your AI about Arrowhead Research.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Arrowhead Research's market cap?: Arrowhead Research (ARWR) has a market capitalization of $12.0B and trades on NASDAQ.
What is Arrowhead Research's revenue and profitability?: Arrowhead Research generated $622.0M in trailing twelve-month revenue with a net loss of $300.9M, representing a net margin of -48.4%, with free cash flow of $561.0M. These figures are based on the Q1 2026 filing.
Who are Arrowhead Research's competitors?: Arrowhead Research's key competitors include Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Scienture Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Arrowhead Research partner with?: Arrowhead Research's notable partners include Sarepta Therapeutics, Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, and others.
Where is Arrowhead Research headquartered?: Arrowhead Research is headquartered in United States of America and employs approximately 525 people. It has been publicly traded since 1995.